← Every applicant
Sandoz FDA Approvals
29 new drug approvals and 0 device clearances on file. This applicant is not matched to a listed company.
Newest first
A new drug approval is an original application; a 510(k) is a device shown equivalent to one already sold.
| Product |
|---|
| POMALIDOMIDENew drugAug 31, 2026CAPSULE, ORAL |
| FIDAXOMICINNew drugAug 13, 2026TABLET, ORAL |
| SUGAMMADEX SODIUMNew drugJul 28, 2026SOLUTION, INTRAVENOUS |
| LIRAGLUTIDENew drugJul 1, 2026SOLUTION, SUBCUTANEOUS |
| VASOPRESSINNew drugMay 6, 2026SOLUTION, INTRAVENOUS |
| VASOPRESSINNew drugMay 6, 2026SOLUTION, INTRAVENOUS |
| ENZALUTAMIDENew drugApr 20, 2026TABLET, ORAL |
| DAPAGLIFLOZINNew drugApr 6, 2026TABLET, ORAL |
| NINTEDANIB ESYLATENew drugApr 2, 2026CAPSULE, ORAL |
| MESALAMINENew drugMar 10, 2026CAPSULE, EXTENDED RELEASE, ORAL |
| FLUOROMETHOLONENew drugFeb 12, 2026SUSPENSION/DROPS, OPHTHALMIC |
| SITAGLIPTIN PHOSPHATENew drugJan 14, 2026TABLET, ORAL |
| SITAGLIPTIN AND METFORMIN HYDROCHLORIDENew drugDec 2, 2025TABLET, ORAL |
| IRON SUCROSENew drugAug 8, 2025INJECTABLE, INTRAVENOUS |
| ERIBULIN MESYLATENew drugJun 9, 2025SOLUTION, INTRAVENOUS |
| EDARAVONENew drugDec 23, 2024SOLUTION, INTRAVENOUS |
| LISDEXAMFETAMINE DIMESYLATENew drugJul 26, 2024CAPSULE, ORAL |
| BRIMONIDINE TARTRATENew drugMar 4, 2024SOLUTION/DROPS, OPHTHALMIC |
| CYCLOPHOSPHAMIDENew drugSep 12, 2023SOLUTION, INTRAVENOUS |
| BREXPIPRAZOLENew drugSep 26, 2022TABLET, ORAL |
| PIRFENIDONENew drugJun 13, 2022CAPSULE, ORAL |
| PEMETREXED DISODIUMNew drugMay 26, 2022SOLUTION, INTRAVENOUS |
| PIRFENIDONENew drugApr 28, 2022TABLET, ORAL |
| BRIMONIDINE TARTRATE AND TIMOLOL MALEATENew drugApr 4, 2022SOLUTION/DROPS, OPHTHALMIC |
| TAFLUPROSTNew drugJan 28, 2022SOLUTION/DROPS, OPHTHALMIC |
| ARSENIC TRIOXIDENew drugDec 2, 2021INJECTABLE, INJECTION |
| ALBUTEROL SULFATENew drugJun 1, 2021AEROSOL, METERED, INHALATION |
| FERUMOXYTOLNew drugJan 15, 2021SOLUTION, INTRAVENOUS |
| CYANOCOBALAMINNew drugJan 4, 2021INJECTABLE, INJECTION |